| 05/10/26 | 12:00:04 | 5 Oct 2026 | | AstraZeneca completes equity investment in Summit | RNS |
| 02/10/26 | 07:30:00 | 2 Oct 2026 | | AZ & DS collaboration with Summit for Datroway | RNS |
| 01/10/26 | 15:05:00 | 1 Oct 2026 | | Admission of Further Securities to Trading | RNS |
| 01/10/26 | 15:00:00 | 1 Oct 2026 | | Total Voting Rights | RNS |
| 29/09/26 | 07:00:08 | 29 Sept 2026 | | AstraZeneca announces equity investment in Summit | RNS |
| 23/09/26 | 07:00:04 | 23 Sept 2026 | | Trixeo approved in EU for asthma | RNS |
| 21/09/26 | 07:05:01 | 21 Sept 2026 | | Klygefa recommended for EU approval by CHMP | RNS |
| 21/09/26 | 07:00:10 | 21 Sept 2026 | | Enhertu recommended for approval in EU in early BC | RNS |
| 18/09/26 | 11:00:00 | 18 Sept 2026 | | Director/PDMR Shareholding | RNS |
| 15/09/26 | 15:05:00 | 15 Sept 2026 | | Director/PDMR Shareholding | RNS |
| 15/09/26 | 15:00:00 | 15 Sept 2026 | | Director/PDMR Shareholding | RNS |
| 14/09/26 | 07:00:11 | 14 Sept 2026 | | Update on SERENA-4 Phase III trial | RNS |
| 08/09/26 | 14:00:00 | 8 Sept 2026 | | Imfinzi+Imdelltra improved OS in small cell lung | RNS |
| 07/09/26 | 07:00:08 | 7 Sept 2026 | | Etcamah approved in the US for HR+ breast cancer | RNS |
| 01/09/26 | 15:05:01 | 1 Sept 2026 | | Admission of Further Securities to Trading | RNS |
| 01/09/26 | 15:00:00 | 1 Sept 2026 | | Total Voting Rights | RNS |
| 01/09/26 | 11:00:00 | 1 Sept 2026 | | Admission to Trading - €2.55 billion bond offering | RNS |
| 01/09/26 | 07:30:00 | 1 Sept 2026 | | Enhertu approved in EU for 1L HER2-positive mBC | RNS |
| 01/09/26 | 07:10:02 | 1 Sept 2026 | | Directorate change | RNS |
| 01/09/26 | 07:05:00 | 1 Sept 2026 | | AstraZeneca completes agreement for Zegfrovy | RNS |
| 01/09/26 | 07:00:20 | 1 Sept 2026 | | Tagrisso + Orpathys improved PFS in 1L EGFRm lung | RNS |
| 27/08/26 | 07:00:05 | 27 Aug 2026 | | Tezspire CROSSING trial met primary endpoints | RNS |
| 25/08/26 | 07:00:03 | 25 Aug 2026 | | AstraZeneca prices a €2.55 billion bond offering | RNS |
| 19/08/26 | 11:00:00 | 19 Aug 2026 | | Director/PDMR Shareholding | RNS |
| 17/08/26 | 07:30:01 | 17 Aug 2026 | | Enhertu improved PFS in 1L HER2m lung cancer | RNS |
| 17/08/26 | 07:05:00 | 17 Aug 2026 | | Update on eVOLVE-Lung02 Phase III trial | RNS |
| 17/08/26 | 07:00:09 | 17 Aug 2026 | | Tagrisso+Orpathys improved PFS & OS in EGFRm lung | RNS |
| 03/08/26 | 15:05:00 | 3 Aug 2026 | | Admission of Further Securities to Trading | RNS |
| 03/08/26 | 15:00:00 | 3 Aug 2026 | | Total Voting Rights | RNS |
| 31/07/26 | 07:30:00 | 31 Jul 2026 | | Datroway approved in EU for TNBC | RNS |
| 27/07/26 | 07:10:01 | 27 Jul 2026 | | Update on Ultomiris Phase III trial in HSCT-TMA | RNS |
| 27/07/26 | 07:05:01 | 27 Jul 2026 | | Sone-Ve improved survival in gastric cancers | RNS |
| 27/07/26 | 07:00:06 | 27 Jul 2026 | | Half-year Financial Report | RNS |
| 23/07/26 | 07:00:06 | 23 Jul 2026 | | Etcamah approved in the EU for ER+ breast cancer | RNS |
| 14/07/26 | 07:00:06 | 14 Jul 2026 | | AstraZeneca licenses novel EGFR inhibitor | RNS |
| 09/07/26 | 07:00:04 | 9 Jul 2026 | | Update on CARDIO-TTRansform Phase III trial | RNS |
| 01/07/26 | 15:05:00 | 1 Jul 2026 | | Admission of Further Securities to Trading | RNS |
| 01/07/26 | 15:00:01 | 1 Jul 2026 | | Total Voting Rights | RNS |
| 29/06/26 | 07:30:01 | 29 Jun 2026 | | Enhertu approved in EU for HER2+ solid tumours | RNS |
| 29/06/26 | 07:00:13 | 29 Jun 2026 | | Datroway recommended for approval in EU for TNBC | RNS |
| 15/06/26 | 07:00:09 | 15 Jun 2026 | | Truqap approved in US for prostate cancer | RNS |
| 01/06/26 | 15:05:01 | 1 Jun 2026 | | Admission of Further Securities to Trading | RNS |
| 01/06/26 | 15:00:00 | 1 Jun 2026 | | Total Voting Rights | RNS |
| 29/05/26 | 07:00:05 | 29 May 2026 | | Imfinzi approved in US for early bladder cancer | RNS |
| 27/05/26 | 07:00:06 | 27 May 2026 | | US FDA decision date on camizestrant extended | RNS |
| 26/05/26 | 07:00:17 | 26 May 2026 | | Enhertu recommended in EU for HER2+ solid tumours | RNS |
| 26/05/26 | 07:00:17 | 26 May 2026 | | Camizestrant recommended for breast cancer in EU | RNS |
| 26/05/26 | 07:00:15 | 26 May 2026 | | Datroway approved in US for 1L triple-negative BC | RNS |
| 18/05/26 | 15:00:00 | 18 May 2026 | | Director/PDMR Shareholding | RNS |
| 18/05/26 | 07:05:00 | 18 May 2026 | | Enhertu approved in two HER2+ early BC settings | RNS |
